8-K: Myomo Q2 Revenue Up 28%, Cuts Full-Year Guidance

Myomo, Inc. reported a 28% increase in second-quarter revenue to $9.7 million but significantly lowered its full-year 2025 revenue guidance due to challenges in lead quality and pipeline conversion.

Summary

• Second quarter 2025 revenue reached $9.7 million, marking a 28% increase compared to Q2 2024.
• Revenue units for the quarter were 178, up 13% year-over-year, with an average selling price (ASP) of approximately $54,200, up 14%.
• 56% of Q2 2025 revenue was derived from Medicare Part B patients.
• Orders and insurance authorizations for MyoPro units decreased by 3% to 207 units.
• The backlog of insurance authorizations and orders not yet converted to revenue stood at 230 units as of June 30, 2025, an 18% decrease.
• The patient pipeline grew by 37% to 1,611 candidates as of June 30, 2025, with 816 new candidates added in Q2, up 49%.
• Gross margin for Q2 2025 was 62.7%, down 810 basis points from 70.8% in Q2 2024, primarily due to higher material and overhead spending.
• Operating expenses increased by 65% to $10.6 million, driven by higher payroll, increased engineering activity, and a 162% rise in advertising expenditures to $2.2 million.
• Cost per direct billing pipeline add increased by 89% to $2,926 due to lower quality leads from digital advertising algorithm changes.
• Net loss for Q2 2025 was $4.6 million, or $0.11 per share, compared to a net loss of $1.1 million, or $0.03 per share, in Q2 2024.
• Adjusted EBITDA for Q2 2025 was $(4.0) million, compared to $(1.2) million in Q2 2024.
• Cash, cash equivalents, and short-term investments were $15.5 million as of June 30, 2025.
• Cash used in operating activities was $8.9 million for Q2 2025, significantly up from $1.9 million in Q2 2024.
• The company reduced its workforce by approximately 8% in July and is eliminating certain outside services, expecting to reduce cash expenditures by at least $2 million over the next 12 months.
• Full-year 2025 revenue guidance was updated to a range of $40 million to $42 million, down from the previous guidance of $50 million to $53 million.
• Third quarter 2025 revenue is expected to be in the range of $9.5 million to $10.0 million.

Sentiment

Score: 3

Explanation: While revenue growth is positive, the significant reduction in full-year guidance, widening losses, increased cash burn, and operational challenges related to lead quality and conversion indicate a negative outlook. The company is taking corrective actions, but the immediate financial impact is adverse.

Positives

• Revenue increased by 28% to $9.7 million in Q2 2025 compared to Q2 2024, exceeding management's expectations.
• Year-to-date revenue grew by 73% to $19.5 million compared to the same period in 2024.
• The patient pipeline expanded significantly, with 816 new candidates added in Q2 2025 (up 49%) and the total pipeline reaching 1,611 patients (up 37%).
• 53% of Q2 revenue units were generated from intra-quarter authorizations and orders, indicating high velocity of revenue conversion.
• The company has taken decisive actions, including workforce reduction and spending cuts, to improve operating performance and reduce cash expenditures by at least $2 million over the next 12 months.
• Cash, cash equivalents, and short-term investments of $15.5 million are believed to be sufficient to fund operations for the next 12 months.
• Issues with a DME MAC payment hold and aged receivables were resolved at the beginning of August, improving cash flow.

Negatives

• Full-year 2025 revenue guidance was significantly lowered to $40 million-$42 million from $50 million-$53 million.
• Gross margin decreased by 810 basis points to 62.7% in Q2 2025, primarily due to higher material and overhead spending.
• Operating expenses increased substantially by 65% to $10.6 million, leading to a higher operating loss of $4.6 million compared to $1.1 million in Q2 2024.
• Net loss widened to $4.6 million ($0.11 per share) in Q2 2025 from $1.1 million ($0.03 per share) in Q2 2024.
• Adjusted EBITDA worsened to $(4.0) million in Q2 2025 from $(1.2) million in Q2 2024.
• Orders and insurance authorizations for MyoPro units decreased by 3% to 207 units.
• Backlog decreased by 18% to 230 units as of June 30, 2025.
• Cost per direct billing pipeline add increased by 89% to $2,926 due to lower quality leads from digital advertising algorithm changes.
• Cash used in operating activities significantly increased to $8.9 million in Q2 2025 from $1.9 million in Q2 2024, with a normalized cash burn of $4.9 million.
• Lower conversion rates from pipeline adds to authorizations and orders were observed due to patient response, clinical presentations, and enhanced outcome focus disqualifying more patients.

Risks

• Ability to obtain sufficient reimbursement from third-party payers for products.
• Dependence on external sources for financing operations.
• Ability to scale the business to achieve positive cash flow from operations.
• Revenue concentration with Medicare and a particular insurance payer.
• Ability to continue normal operations and patient interactions without supply chain disruption.
• Effectiveness of marketing and commercialization efforts.
• Ability to obtain and maintain strategic collaborations and realize their intended results.
• Ability to remediate the material weakness in internal control over financial reporting.
• Uncertainty regarding product development programs, including improving existing products and developing new ones.
• Ability to maintain and grow reputation and achieve market acceptance of products.
• Uncertainty regarding clinical research program and clinical results.
• Ability to maintain adequate protection of intellectual property and avoid violation of others' intellectual property rights.
• Ability to gain and maintain regulatory approvals.
• Ability to compete and succeed in a highly competitive and evolving industry.
• General market, economic, environmental, and social factors that may affect the evaluation, fitting, delivery, and sale of products to patients.

Future Outlook

The company updated its full-year 2025 revenue guidance to a range of $40 million to $42 million, a significant reduction from the previous guidance of $50 million to $53 million, but still representing an increase of 23% to 29% versus 2024. Revenue for the third quarter of 2025 is expected to be in the range of $9.5 million to $10.0 million. Management expects actions to improve lead quality and pipeline conversion, along with maintaining current advertising spending, to positively impact operating metrics in the near term. Normalized cash burn is expected to be approximately $4.9 million in the second half of the year, and current cash is believed to be sufficient to fund operations for the next 12 months.

Management Comments

• "Second quarter revenues exceeded our expectations with 28% growth as we further strengthened our ability to convert current quarter authorizations and orders into revenue. However, several forward-looking operating metrics were not as strong as we anticipated due to factors affecting lead quality and pipeline conversion."
• "We are taking decisive action to improve lead quality and pipeline conversion, positioning us for stronger operating performance. Specifically, we are shifting our advertising focus from digital advertising toward television, which in recent experience generated higher quality leads with stronger patient engagement."
• "We are also using our clinical team to engage with therapists and physicians nationwide to expand the number of healthcare professionals that understand the benefits of the MyoPro in improving patient outcomes. By enhancing our eco-system of knowledgeable providers and moving forward in the patients' continuum of care, we expect to secure additional patient referrals for us and our O&P partners."
• "We believe there are three factors impacting our key operating metrics. First is the quality of leads being generated after applying changes to our digital advertising in response to the algorithm change. Second is lower conversion rates to both pipeline adds and authorizations and orders. The key drivers are patient response after they contact us, the clinical presentations of patients we're seeing and the enhanced outcome focus of our clinical team which is disqualifying more patients from MyoPro eligibility. Third is a cycle time effect related to pipeline adds. A retrospective cohort analysis shows that 40-50% of pipeline adds in a given quarter come from leads generated a year or more ago. Therefore, we believe that a significant amount of our 2025 advertising spending will generate pipeline adds in 2026 and beyond."
• "The actions we are taking, along with maintaining the current level of advertising spending, are expected to positively impact our operating metrics in the near term."
• "Several factors contributed to the elevated use of cash, including the higher operating loss, capital expenditures for software development, improvements to the additional space in our manufacturing facility and demo units for clinicians and the O&P channel. Cash use also reflected higher cash requirements for working capital, including payment of 2024 incentive compensation of $2.9 million, a payment hold by one of the DME MACs in order to process our address change, which impacted cash flow by approximately $1.5 million, a further increase in days sales outstanding due to pre-payment audits being undertaken by two of the other DME MACs and a repayment to an insurance payer for an overpayment in a prior period."
• "The payment hold has been removed and the aged receivables were paid at the beginning of August."
• "Regarding the pre-payment audits, most claims with audit determinations have been paid and only a handful have been denied, which we intend to appeal. Excluding non-recurring cash outflows, our normalized cash burn was $4.9 million in the second quarter, which is a close approximation of the total cash burn we expect in the second half of the year."
• "We are updating our 2025 revenue guidance to a range of $40 million to $42 million, compared with our previous guidance range of $50 million to $53 million, which represents an increase of 23% to 29% versus 2024. Revenue for the third quarter of 2025 is expected to be in the range of $9.5 million to $10.0 million."

Industry Context

Myomo operates in the wearable medical robotics sector, specifically targeting neurological disorders and upper-limb paralysis. This niche market is characterized by high R&D costs, significant regulatory hurdles, and reliance on insurance reimbursement. The company's challenges with lead quality from digital advertising and conversion rates highlight the evolving landscape of patient acquisition in healthcare, where traditional methods like television advertising and direct clinician engagement may still yield higher quality leads than purely digital channels, especially for specialized medical devices. The increased focus on clinical outcomes and patient eligibility also reflects a broader industry trend towards value-based care and stricter reimbursement criteria.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark Myomo's performance against global industry standards. Therefore, a direct assessment of its results in the context of global benchmarks is not possible based solely on the provided information.
• However, the significant reduction in revenue guidance and increased cash burn suggest that Myomo's operational challenges and financial performance may be lagging behind the growth expectations typically seen in high-growth medical technology sectors, especially given the high gross margins which indicate strong product value but are offset by high operating expenses.

Stakeholder Impact

• **Shareholders:** Face increased losses and a significant reduction in revenue guidance, potentially leading to negative share price performance. The increased cash burn and utilization of credit facilities could raise concerns about future dilution or financing needs.
• **Employees:** An 8% workforce reduction in July indicates job losses, impacting employee morale and potentially operational capacity.
• **Customers (Patients):** The company's efforts to improve lead quality and clinical engagement aim to better serve patients by ensuring MyoPro reaches those who can most benefit, potentially improving patient outcomes and access.
• **Suppliers:** Higher material and overhead spending, while contributing to lower gross margins, suggests continued demand for components and services.
• **Creditors:** The company borrowed $4.0 million against its credit facilities, increasing its debt obligations. However, the belief that cash is sufficient for the next 12 months may reassure creditors in the short term.

Next Steps

• Shift advertising focus from digital to television to generate higher quality leads and improve patient engagement.
• Utilize the clinical team to engage with therapists and physicians nationwide to expand understanding and referrals for MyoPro.
• Continue efforts to improve lead quality and pipeline conversion rates.
• Maintain current levels of advertising spending to positively impact operating metrics in the near term and generate future pipeline adds.
• Continue to appeal denied claims from pre-payment audits by DME MACs.
• Hold a conference call on August 11, 2025, at 4:30 p.m. Eastern time to discuss results and answer questions.

Key Dates

Recommendation

Despite revenue growth, the significant reduction in full-year guidance, widening net losses, increased cash burn, and operational inefficiencies (declining gross margin, higher cost per lead, lower conversion rates) present substantial concerns. While management is taking corrective actions, the immediate financial deterioration and the downgrade in future expectations suggest a challenging period ahead. The stock is likely to face downward pressure, making a 'sell' recommendation appropriate for investors seeking to mitigate risk.

Keywords

Myomo, MyoPro, wearable medical robotics, neurological disorders, upper-limb paralysis, orthosis, EMG signals, stroke rehabilitation, brachial plexus injury, traumatic brain injury, spinal cord injury, neuromuscular disease, medical device, Q2 earnings, revenue guidance, patient pipeline, gross margin, operating expenses, net loss, cash position, healthcare technology